Craig Masse, PhD
Craig E. Masse has over ten years of experience in the biotechnology industry with a strong track record of delivering high-value development candidates. Prior to joining Nimbus, Masse served as group leader of medicinal chemistry at Concert Pharmaceuticals and oversaw the creation of three development candidates that entered into clinical trials, each within eighteen months. During this time, Masse led multidisciplinary drug-discovery project teams including two anti-infective programs, supported strategic assessment of programs for portfolio management, and provided scientific support for business development that resulted in a $1 billion multi-product transaction with GlaxoSmithKline. Prior to Concert, Masse started his career as a research scientist at Amgen-Cambridge where he worked in the oncology, inflammation, and neuroscience therapeutic areas. He is an inventor on over twenty patents and has co-authored over fifty scientific publications including several book chapters.
Masse earned his PhD in synthetic organic chemistry from Boston University and conducted postdoctoral research at Harvard University with Professor David A. Evans.
- PhD Boston University